CN115916770B - H4拮抗剂化合物 - Google Patents

H4拮抗剂化合物 Download PDF

Info

Publication number
CN115916770B
CN115916770B CN202180030226.4A CN202180030226A CN115916770B CN 115916770 B CN115916770 B CN 115916770B CN 202180030226 A CN202180030226 A CN 202180030226A CN 115916770 B CN115916770 B CN 115916770B
Authority
CN
China
Prior art keywords
acid
compound
pyrazol
methyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180030226.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN115916770A (zh
Inventor
迈尔斯·斯图尔特·康格里夫
夏洛特·菲尔德豪斯
奈杰尔·艾伦·斯温
马克·皮克沃斯
邓肯·罗伯特·汉娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexla Pharmaceuticals Uk Ltd
Original Assignee
Nexla Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70859977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115916770(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nexla Pharmaceuticals Uk Ltd filed Critical Nexla Pharmaceuticals Uk Ltd
Publication of CN115916770A publication Critical patent/CN115916770A/zh
Application granted granted Critical
Publication of CN115916770B publication Critical patent/CN115916770B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180030226.4A 2020-04-22 2021-04-22 H4拮抗剂化合物 Active CN115916770B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005858.2 2020-04-22
GBGB2005858.2A GB202005858D0 (en) 2020-04-22 2020-04-22 H4 Antagonist compounds
PCT/GB2021/050971 WO2021214469A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds

Publications (2)

Publication Number Publication Date
CN115916770A CN115916770A (zh) 2023-04-04
CN115916770B true CN115916770B (zh) 2025-02-28

Family

ID=70859977

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180030226.4A Active CN115916770B (zh) 2020-04-22 2021-04-22 H4拮抗剂化合物

Country Status (12)

Country Link
US (1) US20230167094A1 (https=)
EP (1) EP4139300A1 (https=)
JP (1) JP7671307B2 (https=)
KR (1) KR20230004512A (https=)
CN (1) CN115916770B (https=)
AU (1) AU2021260142A1 (https=)
BR (1) BR112022021395A2 (https=)
CA (1) CA3180853A1 (https=)
GB (1) GB202005858D0 (https=)
IL (1) IL297469A (https=)
MX (1) MX2022013340A (https=)
WO (1) WO2021214469A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
CN113272297A (zh) * 2018-10-19 2021-08-17 赫普泰雅治疗有限公司 作为h4拮抗剂化合物的吡唑衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
WO2009068512A1 (en) * 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
PE20091524A1 (es) * 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
CN113272297A (zh) * 2018-10-19 2021-08-17 赫普泰雅治疗有限公司 作为h4拮抗剂化合物的吡唑衍生物

Also Published As

Publication number Publication date
CN115916770A (zh) 2023-04-04
MX2022013340A (es) 2023-02-22
JP2023522405A (ja) 2023-05-30
KR20230004512A (ko) 2023-01-06
AU2021260142A1 (en) 2022-11-17
BR112022021395A2 (pt) 2022-12-13
GB202005858D0 (en) 2020-06-03
WO2021214469A1 (en) 2021-10-28
EP4139300A1 (en) 2023-03-01
JP7671307B2 (ja) 2025-05-01
IL297469A (en) 2022-12-01
US20230167094A1 (en) 2023-06-01
CA3180853A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EP2727918B1 (en) Compounds and Compositions as Protein Kinase Inhibitors
AU2012273164B2 (en) Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
KR102873380B1 (ko) H4 길항제 화합물
KR101965326B1 (ko) 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물
WO2013026025A1 (en) Cyclohexyl azetidine derivatives as jak inhibitors
WO2012068440A1 (en) Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
US20140005166A1 (en) Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
IL261215B2 (en) Heterocyclic nitrogen compounds from substituted hexadecane - amino: their preparation and their use
CN115916770B (zh) H4拮抗剂化合物
JP2010540422A (ja) チエノピリミジン化合物類
RU2837355C1 (ru) Соединения-антагонисты н4
CN116848125B (zh) H4拮抗剂化合物
RU2821516C2 (ru) Пиразольные производные в качестве соединений-антагонистов h4
TWI480276B (zh) 作為蛋白質激酶抑制劑之化合物及組合物
WO2026021342A1 (zh) 一种杂环类化合物及其在医药上的应用
HK1191936B (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Britain

Address after: Cambridge, County of Cambridge, UK

Applicant after: Nexla Pharmaceuticals UK Ltd.

Address before: Cambridge, County of Cambridge, UK

Applicant before: Heptares Therapeutics Ltd.

Country or region before: Britain

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant